Press Releases

March 13, 2018 News Release 150 150 Nass Valley Gateway

March 13, 2018 News Release

NEWS RELEASE

TERMINATION OF ASSET PURCHASE AGREEMENTS WITH “ITHL” AND “IXIVP” AND EXECUTION OF LOI WITH ADVANCED BIOCEUTICALS LIMITED

Vancouver, BC, Canada – March 13 2018

Nass Valley Gateway Ltd. (the “Company” or “Nass Valley”), trading on the  Canadian Securities Exchange (“CSE”) under the trading Symbol “NVG” and on Deutsche Borse,  Frankfurt under the trading Symbol 3NVN, wishes to announce that it has terminated the agreements with IXI Treasury Holdings Ltd.(“ITHL”) and IXI Ventures PLC (“IXIVP”) which were announced by the Company on March 2, 2017 and September 27, 2017 respectively as the requested financial statements, audited by a qualified international audit firm, to verify the to be acquired assets, were not supplied.  The reader is encouraged to visit the Company’s monthly progress reports since 2017 on the Canadian Securities Exchange (“CSE”) website http://thecse.com/en/listings/cleantech/nass-valley-gateway-ltd.Nass Valley is pleased to announce that it has entered into a non-binding LOI, dated March 9, 2018, as basis for a Definitive Acquisition and Share Exchange Agreement (“DASE-Agr” ) with Advanced Bioceutical Limited, a New Jersey Limited Liability Company (the “Target” or “ABL”) that upon completion will become a wholly owned subsidiary of Nass Valley as “Resulting Issuer”. The Acquisition will be a share exchange between the Resulting Issuer as Parent company and ABL as wholly owned subsidiary conditional upon Regulatory Approval.ABL is engaged in the sale of Durable Medical Equipment (DME) and Cannabidiol (CBD) with zero THC content for internal use including CBD infused skin, bath, and body care products (the “ABL-Business”).ABL’s business was mostly concentrated in the states of New York, New Jersey, and Florida for last 25 years serving patients throughout the US and its main operations are presently conducted through its wholly owned subsidiary, Pro-Thotics Technology Inc. (PTI). PTI had in 2017 a strong balance sheet and earnings, with audited revenues for 2017 in excess of C$3.2 million. During PTI’s 25-year history, 200,000 patients located throughout the U.S. and Puerto Rico were provided relief from pain and medical issues through the purchase of PTI’s durable medical equipment products. Determined to expand upon this pain relief concept, ABL will aggressively continue to focus on the CBD marketplace as well as open offices in Maryland, Virginia, California and Washington, DC and expand its current New Jersey operations.With its operations, presently conducted by PTI, in New York, New Jersey and Florida and its existing national marketing and advertising campaigns, ABL has action plans to establish inhouse manufactured CBD products, CBD infused skin, bath, and body care products to the U.S.Upon the approval of the Canadian Securities Exchange (“CSE”), Nass Valley as Resulting Issuer will acquire 100 % of the outstanding shares of ABL including its subsidiaries in exchange for the issuance of newly issued common shares issued at ten cents Canadian dollars (C$0.10) per share and equal to approximately 90 % of all of the issued and outstanding securities of the Resulting Issuer on a fully diluted basis. Based on a review of 12 public companies trading in Australia, Canada and the US an adjusted average to revenue and average market capitalization to EBITDA was calculated to determine a deemed value of     C$43,250,000 for the proposed acquisition of ABL and its subsidiaries.Subsequent to the CSE approval, ABL and its subsidiary will be wholly owned by the Resulting Issuer with will include an existing, very experienced and knowledgeable management team. The proposed transaction will be considered a Reversed Take Over (“RTO”) under the rules of the CSE and as such will require shareholder approval or the written consent of more than 50% of a minimum of five registered shareholders for the final approval of the CSE.Dieter Peter, President &CEO, commented: “This potential transaction will place the Company in a strong strategic position with a strong asset base and earnings and a tremendous upside potential within a very attractive market segment. I am therefore especially delighted that ABL’s young and experienced management team as major future shareholders agreed to join Nass Valley’s future management and Board of Directors and will bring tremendous value to the company’s future growing with their marketing and operational experience including financial management and risk estimations.”The LOI is the basis for the shortly to be executed DASE-Agr. The Company’s shares have been halted for quite some time and will not resume trading at this time pending approval of the transaction by the CSE.

We seek Safe Harbor.

For further information please contact:

Dieter Peter, President & CEO

Phone: 604-617-6794

Neither the CSE nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of the contents of this news release.

March 27, 2018 News Release 150 150 Nass Valley Gateway

March 27, 2018 News Release

NEWS RELEASE

NASS VALLEY GATEWAY EXECUTES DEFINITIVE ACQUISITION AND SHARE EXCHANGE AGREEMENT WITH ADVANCED BIOCEUTICALS

Vancouver, BC, Canada – March 27 2018

Nass Valley Gateway Ltd. (the “Company” or “Nass Valley”), trading on the Canadian Securities Exchange (“CSE”) under the trading Symbol “NVG” and on Deutsche Borse, Frankfurt under the trading Symbol 3NVN, is pleased to announce that, on March 22, 2018, it executed the Definitive Acquisition and Share Exchange Agreement (“DASE-Agr” ) with Advanced Bioceutical Limited, a privately owned Limited Liability Company (“ABL”) incorporated under the Laws of New Jersey. Under the terms of the agreement ABL and its wholly owned subsidiary Pro-Thotics Technology Inc. (“PTI”), a New York private corporation, will become wholly owned subsidiaries of Nass Valley as the “Resulting Issuer”. The DASE-Agr constitutes a valid and legally binding agreement, enforceable against the Parties, in accordance with its respective terms.

ABL negotiated the 100% acquisition of PTI in 2017 which is a company engaged in the sale of Durable Medical Equipment (“DME”) with principal operations in New York, New Jersey and Florida. Since its inception in 1988, PTI has been one of the Northeast’s premier supplier specializing in orthotics and prosthetics for those in need of pain relief. PTI has a strong balance sheet and will expand its current DME business nationwide into areas of the U.S. not currently served by PTI as well as expand its business through the strategic acquisition of related companies. During PTI’s more than 25-year history, it has served over 200,000 patients located throughout the U.S. and Puerto Rico (the PTI-Business”), and provided relief from pain and medical issues through its Business.

ABL is focusing on expanding upon this pain relief concept, and will aggressively continue entering the Cannabidiol (“CBD”) with zero THC content for internal and external use including CBD infused skin, bath, and body care products (the “ABL-Business”). In conjunction with the ABL-Business, it plans to horizontally integrate into an exciting new area for pain and health relief; CBD and related products. The markets for CBD products are growing at an exponential pace and ABL as subsidiary of NVG may also entertain partnerships with companies engaged in the production and manufacturing of products related to its business.

With its operations, presently conducted by PTI, in New York, New Jersey and Florida and its existing national marketing and advertising campaigns, ABL has action plans to establish inhouse manufactured CBD products, CBD infused skin, bath, and body care products to the U.S.

On the Effective-Date the owners of ABL and PTI will transfer to Nass Valley as the Resulting Issuer an aggregate of 100% (one hundred percent) of their ownership interest, and Nass Valley shall issue an aggregate of 89.27 % of fully paid and nonassessable common shares of the Resulting Issuer’s shares (the “Acquisition-Shares”) in exchange for 100 % of the ownership interest of ABL and PTI.

The Parties agreed not to change the name of the Company after the approval of the transaction. It was further agreed that Mr. Dieter Peter will be the Chairman of Nass Valley, John Affenita, the founder of ProThotics Inc and an ABC and BOC Orthotist and Prosthetist, serving the O&P field for 20 years will become the Company’s CEO and Dr. Samuel Alawieh, a Pharmacologist and highly respected scientist with significant experience in many aspects of CBD R&D, has agreed to become COO of Nass Valley Gateway.

The proposed transaction is considered a Reversed Take Over (“RTO”) under the rules of the CSE and requires the approval of the disclosure document (the 2A Listing Statement). The Company has obtained the written approval and consent of 54.75% from the required minimum of five registered shareholders pending the approval of the transaction by the CSE.

Dieter Peter, President & CEO, commented: “This transaction will place Nass Valley in a strong strategic position with a tremendous upside potential. I am especially delighted that ABL’s and PTI’s young and experienced management team, Mr. Gregory Vax and Mr. Michael Racaniello as major shareholders of the resulting issuer, have agreed to join Nass Valley’s future management and Board of Directors and also remain as executive managers and driving forces with ABL and PTI”.

For further information please contact: Dieter Peter, President & CEO Phone: 604-617-6794

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Nass Valley’s periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should, aware” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements including statements related to Nass Valley’s transactions and business related to cannabis and future news releases.

Although Nass Valley has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited operating history or when very limited due diligence was performed or may be engaged in activities currently considered illegal under US Federal laws; change in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; and regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Nass Valley disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Nass Valley does not assume any liability for disclosure relating to any other company mentioned herein.

Neither the CSE nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of the contents of this news release.